|
1
|
Tabrizian P, Roayaie S and Schwartz ME:
Current management of hepatocellular carcinoma. World J
Gastroenterol. 20:10223–10237. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang H and Chen L: Tumor microenviroment
and hepatocellular carcinoma metastasis. J Gastroenterol Hepatol.
28(Suppl 1): S43–S48. 2013. View Article : Google Scholar
|
|
3
|
Kondo F, Kondo Y, Nagato Y, Tomizawa M and
Wada K: Interstitial tumour cell invasion in small hepatocellular
carcinoma. Evaluation in microscopic and low magnification views. J
Gastroenterol Hepatol. 9:604–612. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tomizawa M, Kondo F and Kondo Y: Growth
patterns and interstitial invasion of small hepatocellular
carcinoma. Pathol Int. 45:352–358. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tomizawa M, Shinozaki F, Sugiyama T,
Yamamoto S, Sueishi M and Yoshida T: Sorafenib suppresses the cell
cycle and induces the apoptosis of hepatocellular carcinoma cell
lines in serum-free media. Exp Ther Med. 1:863–866. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen RX, Song HY, Dong YY, Hu C, Zheng QD,
Xue TC, Liu XH, Zhang Y, Chen J, Ren ZG, et al: Dynamic expression
patterns of differential proteins during early invasion of
hepatocellular carcinoma. PLoS One. 9:e885432014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vandooren J, Van den Steen PE and
Opdenakker G: Biochemistry and molecular biology of gelatinase B or
matrix metalloproteinase-9 (MMP-9): The next decade. Crit Rev
Biochem Mol Biol. 48:222–272. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li H, Zhang K, Liu LH, Ouyang Y, Bu J, Guo
HB and Xiao T: A systematic review of matrix metalloproteinase 9 as
a biomarker of survival in patients with osteosarcoma. Tumour Biol.
35:5487–5491. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu D, Guo H, Li Y, Xu X, Yang K and Bai
Y: Association between polymorphisms in the promoter regions of
matrix metalloproteinases (MMPs) and risk of cancer metastasis: A
meta-analysis. PLoS One. 7:e312512012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zarogoulidis P, Katsikogianni F, Tsiouda
T, Sakkas A, Katsikogiannis N and Zarogoulidis K: Interleukin-8 and
interleukin-17 for cancer. Cancer Invest. 32:197–205. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pez F, Lopez A, Kim M, Wands JR, de Caron
Fromentel C and Merle P: Wnt signaling and hepatocarcinogenesis:
Molecular targets for the development of innovative anticancer
drugs. J Hepatol. 59:1107–1117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fujimoto T, Tomizawa M and Yokosuka O:
SiRNA of frizzled-9 suppresses proliferation and motility of
hepatoma cells. Int J Oncol. 35:861–866. 2009.PubMed/NCBI
|
|
13
|
Wang YQ, Wang F, Deng XQ, Sheng J, Chen SY
and Su J: Delivery of therapeutic AGT shRNA by PEG-Bu for
hypertension therapy. PLoS One. 8:e686512013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Knorr R: Treatment of tapeworm with
Yomesan in 36 patients. Med Lav. 55:1937–1938. 1960.(In German).
PubMed/NCBI
|
|
15
|
Mwape KE, Phiri IK, Praet N, Muma JB, Zulu
G, Van den Bossche P, de Deken R, Speybroeck N, Dorny P and Gabriël
S: Taenia solium Infections in a rural area of Eastern Zambia-a
community based study. PLoS Negl Trop Dis. 6:e15942012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sack U, Walther W, Scudiero D, Selby M,
Kobelt D, Lemm M, Fichtner I, Schlag PM, Shoemaker RH and Stein U:
Novel effect of antihelminthic Niclosamide on S100A4-mediated
metastatic progression in colon cancer. J Natl Cancer Inst.
103:1018–1036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tomizawa M, Shinozaki F, Motoyoshi Y,
Sugiyama T, Yamamoto S, Sueishi M and Yoshida T: Niclosamide
suppresses Hepatoma cell proliferation via the Wnt pathway. Onco
Targets Ther. 6:1685–1693. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen M, Wang J, Lu J, Bond MC, Ren XR,
Lyerly HK, Barak LS and Chen W: The anti-helminthic niclosamide
inhibits Wnt/Frizzled1 signaling. Biochemistry. 48:10267–10274.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wieland A, Trageser D, Gogolok S, Reinartz
R, Höfer H, Keller M, Leinhaas A, Schelle R, Normann S, Klaas L, et
al: Anticancer effects of niclosamide in human glioblastoma. Clin
Cancer Res. 19:4124–4136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takahashi-Yanaga F and Sasaguri T:
GSK-3beta regulates cyclin D1 expression: A new target for
chemotherapy. Cell Signal. 20:581–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takayasu H, Horie H, Hiyama E, Matsunaga
T, Hayashi Y, Watanabe Y, Suita S, Kaneko M, Sasaki F, Hashizume K,
et al: Frequent deletions and mutations of the beta-catenin gene
are associated with overexpression of cyclin D1 and fibronectin and
poorly differentiated histology in childhood hepatoblastoma. Clin
Cancer Res. 7:901–908. 2001.PubMed/NCBI
|
|
22
|
Ye T, Xiong Y, Yan Y, Xia Y, Song X, Liu
L, Li D, Wang N, Zhang L, Zhu Y, et al: The anthelmintic drug
niclosamide induces apoptosis, impairs metastasis and reduces
immunosuppressive cells in breast cancer model. PLoS One.
9:e858872014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Y, Li PK, Roberts MJ, Arend RC, Samant
RS and Buchsbaum DJ: Multi-targeted therapy of cancer by
niclosamide: A new application for an old drug. Cancer Lett.
349:8–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
